Harlendea Nicyela J, Harlendo Kent
Pathology, Tarumanagara University, Jakarta, IDN.
Clinical Pathology, Sebelas Maret University, Solo, IDN.
Cureus. 2024 Oct 23;16(10):e72190. doi: 10.7759/cureus.72190. eCollection 2024 Oct.
Burkitt lymphoma (BL) is a form of non-Hodgkin's lymphoma (NHL) that is characterized by high aggressiveness and arises from the germinal center of B cells. The prevalence of BL in adulthood is less than 5%. However, it encompasses 40% of all childhood NHL. Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma. It accounts for approximately 25% of all NHL cases worldwide. The differentiation between BL and DLBCL is more clear in theory than in daily practice. However, it is important because it implies different treatments. Compared to the other indolent small cell lymphomas, DLBCLs and BLs show higher Ki-67 index values. The Ki-67 levels in DLBCL typically range from 40% to 90%, while BL has a high Ki-67 positivity, nearing 100%. The aim of this article is to explore and review the function of Ki-67 as a differential marker for BL and DLBCL. An all-language literature search was conducted on MEDLINE, Cochrane, Embase, and Google Scholar until March 2024. The following search strings and Medical Subject Heading (MeSH) terms were used: "Ki-67," "Burkitt lymphoma," and "diffuse large B-cell lymphoma." We comprehensively reviewed the literature on BL, DLBCL, and the Ki-67 marker.
伯基特淋巴瘤（BL）是一种非霍奇金淋巴瘤（NHL），其特点是侵袭性高，起源于B细胞生发中心。BL在成年人中的患病率低于5%。然而，它占所有儿童NHL的40%。弥漫性大B细胞淋巴瘤（DLBCL）是最常见的淋巴瘤。它约占全球所有NHL病例的25%。BL和DLBCL之间的鉴别在理论上比在日常实践中更清晰。然而，这很重要，因为它意味着不同的治疗方法。与其他惰性小细胞淋巴瘤相比，DLBCL和BL显示出更高的Ki-67指数值。DLBCL中的Ki-67水平通常在40%至90%之间，而BL的Ki-67阳性率很高，接近100%。本文的目的是探讨和综述Ki-67作为BL和DLBCL鉴别标志物的作用。截至2024年3月，在MEDLINE、Cochrane、Embase和谷歌学术上进行了全语言文献检索。使用了以下检索词和医学主题词（MeSH）：“Ki-67”、“伯基特淋巴瘤”和“弥漫性大B细胞淋巴瘤”。我们全面回顾了关于BL、DLBCL和Ki-67标志物的文献。
